- Home
- OTLK vs JVA Comparison
OTLK vs JVA Comparison
Compare OTLK & JVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- JVA
- Stock Information
- Founded
- OTLK 2010
- JVA 1971
- Country
- OTLK United States
- JVA United States
- Employees
- OTLK N/A
- JVA N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- JVA Packaged Foods
- Sector
- OTLK Health Care
- JVA Consumer Staples
- Exchange
- OTLK Nasdaq
- JVA Nasdaq
- Market Cap
- OTLK 56.3M
- JVA 47.3M
- IPO Year
- OTLK 2016
- JVA 2005
- Fundamental
- Price
- OTLK $1.48
- JVA $6.42
- Analyst Decision
- OTLK Strong Buy
- JVA
- Analyst Count
- OTLK 5
- JVA 0
- Target Price
- OTLK $10.20
- JVA N/A
- AVG Volume (30 Days)
- OTLK 467.0K
- JVA 344.2K
- Earning Date
- OTLK 02-14-2025
- JVA 03-21-2025
- Dividend Yield
- OTLK N/A
- JVA N/A
- EPS Growth
- OTLK N/A
- JVA N/A
- EPS
- OTLK N/A
- JVA 0.39
- Revenue
- OTLK N/A
- JVA $78,562,298.00
- Revenue This Year
- OTLK N/A
- JVA N/A
- Revenue Next Year
- OTLK $288.46
- JVA N/A
- P/E Ratio
- OTLK N/A
- JVA $16.70
- Revenue Growth
- OTLK N/A
- JVA 15.24
- 52 Week Low
- OTLK $0.87
- JVA $1.15
- 52 Week High
- OTLK $12.85
- JVA $9.93
- Technical
- Relative Strength Index (RSI)
- OTLK 41.52
- JVA 51.80
- Support Level
- OTLK $1.38
- JVA $6.32
- Resistance Level
- OTLK $1.56
- JVA $9.93
- Average True Range (ATR)
- OTLK 0.12
- JVA 1.11
- MACD
- OTLK 0.02
- JVA -0.07
- Stochastic Oscillator
- OTLK 59.26
- JVA 22.52
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About JVA Coffee Holding Co. Inc.
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.